1. Best Practices in the Multidisciplinary Management of Advanced Bladder Cancer

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. KEYNOTE-045: Background

5. KEYNOTE-045: Updated Results

6. KEYNOTE-045: Pembrolizumab Toxicity

7. KEYNOTE-052: Updated Results

8. KEYNOTE-052: Results in Context

9. ECHO-202/KEYNOTE-037: Overview

10. ECHO-202/KEYNOTE-037: Results

11. Finding the Right Combinations

12. Updated Analysis: Enfortumab Vedotin

13. Other Updates

14. Case 1

15. Case 1 (cont)

16. Case 1: Multidisciplinary Management

17. Case 2

18. Case 2 (cont)

19. Case 2 (cont)

20. Phase 1a Study of Atezolizumab in mUC Two-Year Clinical Update

21. Treatment for Cisplatin-Ineligible Patients With mUC IMvigor 210 – Atezolizumab Phase 2 Study

22. Determining Disease Response

23. Raising Awareness of Emerging Therapy AEs

24. Adverse Events With Checkpoint Inhibitors

25. Caring for Newly Diagnosed Patients Faculty Experience

26. Patient Resources

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)